Skip to contentI
iBio, Inc.
I
IBIOiBio, Inc. Q2 2025 · 10-Q
Revenue$200.00K$200.00K— vs Q2 2024 Net Income-$4.36M-$4.36MN/M vs Q2 2024 EPS Diluted-$0.48-$0.48N/M vs Q2 2024 Operating Income-$4,419,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
iBio, Inc. · CIK 1420720 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$3,870,000— Margins · derivedOperating margin-2209.5%
Net margin-2182.0%
ended Dec 31, 2024 · filed Feb 10, 2025 · 41 d after period end